ProQR Therapeutics N.V. (NASDAQ:PRQR) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

Other analysts also recently issued reports about the company. Zacks Investment Research upgraded ProQR Therapeutics N.V. from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research report on Tuesday, August 22nd. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of ProQR Therapeutics N.V. in a research report on Tuesday, June 20th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $14.30.

Shares of ProQR Therapeutics N.V. (PRQR) traded up 1.68% on Friday, reaching $6.05. 140,634 shares of the company’s stock were exchanged. The stock’s market cap is $145.84 million. ProQR Therapeutics N.V. has a one year low of $3.65 and a one year high of $8.70. The company’s 50 day moving average is $5.11 and its 200-day moving average is $4.97.

TRADEMARK VIOLATION NOTICE: “ProQR Therapeutics N.V. (PRQR) Raised to Hold at ValuEngine” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/15/proqr-therapeutics-n-v-prqr-raised-to-hold-at-valuengine.html.

Several large investors have recently added to or reduced their stakes in the company. Redmile Group LLC lifted its position in shares of ProQR Therapeutics N.V. by 2.8% during the second quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock worth $8,301,000 after purchasing an additional 43,050 shares during the last quarter. Artal Group S.A. lifted its position in shares of ProQR Therapeutics N.V. by 25.0% during the second quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $2,600,000 after purchasing an additional 100,000 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of ProQR Therapeutics N.V. during the second quarter worth $2,028,000. Finally, Sphera Funds Management LTD. lifted its position in shares of ProQR Therapeutics N.V. by 65.0% during the first quarter. Sphera Funds Management LTD. now owns 330,000 shares of the biopharmaceutical company’s stock worth $1,650,000 after purchasing an additional 130,000 shares during the last quarter. Institutional investors and hedge funds own 35.93% of the company’s stock.

ProQR Therapeutics N.V. Company Profile

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with MarketBeat.com's FREE daily email newsletter.